#United States #Irvine #James Y. Wang #Epicutis #Signum Biosciences

Epicutis Welcomes Dr. James Y. Wang as Chief Medical Officer

In a significant move to bolster its scientific leadership, Epicutis, a renowned professional skincare brand driven by patented biotechnology from Signum Biosciences, has announced that Dr. James Y. Wang, MD, MBA, will take on the role of Chief Medical Officer. This transition comes as the company gears up for its next phase of growth, with Dr. Wang poised to steer medical strategy, oversee clinical research, and enhance education programs aimed at professionals in dermatology and aesthetics.

Dr. Wang, who has been chairing the Epicutis Scientific Advisory Board since 2025, is a board-certified dermatologist and dermatopathologist. His extensive background includes founding Metropolis Dermatology, a practice that operates five locations across California, offering both medical and cosmetic dermatology services. With a medical degree from Harvard Medical School and an MBA from Harvard Business School, coupled with a dermatology residency at UCLA, Dr. Wang brings a wealth of knowledge and expertise to his new position. His advanced training in dermatopathology further complements his skill set.

Epicutis has differentiated itself in the competitive skincare market by focusing exclusively on professional channels. This includes dermatology practices, medical spas, luxury hotel spas, and an expanding array of wellness and longevity clinics. The brand's unique formulations rely on proprietary molecules that are meticulously developed by scientists at Signum Biosciences, with a track record of over 15 years of peer-reviewed research validating their efficacy.

As Dr. Wang steps into his role, he will have the primary responsibility of ensuring that all product developments and claims made by Epicutis are firmly grounded in clinical evidence. "When I founded Epicutis, I knew that science had to lead our mission," said Maxwell Stock, the Founder and CEO of Epicutis and Signum Biosciences. He emphasized that Dr. Wang’s involvement as Chief Medical Officer places a practicing dermatologist at the forefront of product development, clinical studies, and professional support for those recommending Epicutis to their patients.

Dr. Wang's responsibilities will encompass evaluating incoming research, guiding the design of innovative clinical studies, advising on new product developments, and spearheading educational initiatives. These educational programs are pivotal in helping providers comprehend the biology behind Epicutis products and how they can complement various in-office procedures and prescription treatments.

Dr. Wang expressed his enthusiasm about his new role, stating, "What attracted me to Epicutis was the rigorous scientific foundation of its products. While many skincare lines begin with trends and try to align them with advancing science, Epicutis starts with cutting-edge molecules that reflect genuine skin biology and builds the entire product line around robust scientific evidence. This is a standard I uphold in my own practice, and I am excited to extend this scientific rigor to even more providers and their patients."

The Vision Ahead

With Dr. Wang's leadership, Epicutis is set to enhance its commitment to science-based skincare solutions. As they venture into new markets and expand their product offerings, the brand aims to maintain its core principle of putting clinical evidence at the heart of its business. Industry experts and customers alike can anticipate innovative products that not only embrace the latest research but also cater to the evolving needs of skincare professionals.

For more details about Epicutis and its product offerings, visit www.epicutis.com.

About Epicutis

Epicutis offers a luxurious, science-backed professional skincare line emphasizing skin health rather than aging. Exclusive to skincare professionals, its high-concentration formulas utilize patented active ingredients carefully crafted in small batches by master formulator Masanori Tamura.

About Signum Biosciences

Signum Biosciences is a biotechnology firm dedicated to discovering and developing innovative molecules that effectively manage inflammation and cellular signaling within the skin. Their research journey began in Dr. Jeffry Stock’s lab at Princeton University, focusing on membrane lipid signaling, and covers both professional skincare and medical dermatology education.